Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 9Burkitt Lymphoma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Biphenotypic, Acute 2Down Syndrome 2Waldenstrom Macroglobulinemia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Ann Arbor Stage II Mantle Cell Lymphoma 1Anemia 1

Interventions

navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1auricularum 1Specimen Handling 1Lenalidomide 1Dexamethasone 1Calcium Dobesilate 1Biopsy 12-(5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-(1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Plasmacytoma × dexamethasone acetate × Clear all
NCT03031730 2026-02-10

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

National Cancer Institute (NCI)

Phase 1 Terminated
35 enrolled 10 charts
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡